1-6 of 6
Jeffrey W. Scott
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Phase 2, Multicenter, Nonrandomized, Open-Label Study of Dovitinib (TKI258) in Patients with Relapsed or Refractory Multiple Myeloma with or without t(4;14) Translocation

Christof Scheid, MD, PhD, Donna Reece, Meral Beksac, MD, Andrew Spencer, MD, Natalie Callander, MD, Pieter Sonneveld, MD, Ghulam Kalimi, PhD, Can Cai, Michael Shi, MD, PhD, Jeffrey W. Scott, A. Keith Stewart, MBA, MB, CHB
Journal: Blood
Blood (2012) 120 (21): 4055.
https://doi.org/10.1182/blood.V120.21.4055.4055
Published: 2012
Journal Articles

Activity of Oral Panobinostat (LBH589) in Patients with Myelofibrosis.

Daniel J. DeAngelo, MD, PhD, Andrew Spencer, Thomas Fischer, MD, Thomas Kindler, MD, Oliver G. Ottmann, MD, Miles Prince, MD, Frank J. Giles, MD, MB, FRCPI, FRCPath, Jorge Cortes, MD, Angela Liu, PharmD, Kathryn Parker, PhD, Ying Yan, Jeffrey W. Scott, Kapil N. Bhalla, MD
Journal: Blood
Blood (2009) 114 (22): 2898.
https://doi.org/10.1182/blood.V114.22.2898.2898
Published: 2009
Journal Articles

The Histone Deacetylase Inhibitor LAQ824 Maintains Normal Hematopoietic Progenitor cells (HPC) Associated with Induction of Notch Target Genes and Does Not Eliminate Leukemic HPC in Vitro.

Kerstin Schwarz, Oliver Ottmann, Annette Romanski, Anja Vogel, Jeffrey W. Scott, Hubert Serve, Gesine Bug
Journal: Blood
Blood (2008) 112 (11): 1352.
https://doi.org/10.1182/blood.V112.11.1352.1352
Published: 2008
Journal Articles

Phase IA/II Study of Oral Panobinostat (LBH589), a Novel Pan- Deacetylase Inhibitor (DACi) Demonstrating Efficacy in Patients with Advanced Hematologic Malignancies.

Oliver G. Ottmann, MD, Andrew Spencer, H. Miles Prince, Kapil N. Bhalla, Thomas Fischer, Angela Liu, Kathryn Parker, Muhammad Jalaluddin, Glen Laird, Margaret Woo, Jeffrey W. Scott, Daniel J. DeAngelo
Journal: Blood
Blood (2008) 112 (11): 958.
https://doi.org/10.1182/blood.V112.11.958.958
Published: 2008
Journal Articles

Phase IA/II Study of Oral LBH589, a Novel Deacetylase Inhibitor (DACi), Administered on 2 Schedules, in Patients with Advanced Hematologic Malignancies.

Andrew Spencer, MD, Miles Prince, MD, Daniel J. DeAngelo, MD, Thomas Fischer, MD, Kapil N. Bhalla, MD, Francis J. Giles, MB, MD, FRCPI, FRCPa, Angela Liu, PharmD, Kathryn Parker, PhD, Glen Laird, PhD, Eric Masson, PharmD, John Rediske, PhD, Jeffrey W. Scott, PhD, Oliver G. Ottmann, MD
Journal: Blood
Blood (2007) 110 (11): 907.
https://doi.org/10.1182/blood.V110.11.907.907
Published: 2007
Journal Articles

Laboratory Tumor Lysis Syndrome Complicating LBH589 Therapy in a Patient with Acute Myeloid Leukemia.

Anna Kalff, MBBS, Jake Shortt, MBBS, Julia Farr, Roger McLennan, MBBS, Jeffrey W. Scott, Angela Liu, Andrew Spencer, MBBS
Journal: Blood
Blood (2006) 108 (11): 4554.
https://doi.org/10.1182/blood.V108.11.4554.4554
Published: 2006